Herpesvirus 6 (HHV-6) IgM and IgG Antibodies IFA

Human Herpesvirus 6 (HHV-6) infects nearly all humans, typically before the age of two, and establishes life-long latency. For most of the population, adults will demonstrate antibodies and declining titers with age. Immunocompromised patients however, may experience a primary infection or reactivation of a latent infection, leading to potentially serious complications. The detection of anti-HHV-6 IgM or a fourfold rise in anti-HHV-6 IgG supports a clinical diagnosis.

Procedure

Human IgM and/or IgG antibodies to HHV-6 antigens are detected by indirect fluorescent antibody (IFA) assay. Diluted serum is incubated on a slide containing infected T-lymphoblasts. If specific HHV-6 antibodies are present, they remain bound, are then labeled by an antibody conjugate and finally detected by fluorescence microscopy. The HHV-6 IgM and IgG IFA assays detect but do not distinguish antibodies directed against both HHV-6A and HHV-6B.

Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.

This website uses cookies

We use cookies to understand how you use our site and to improve your experience. Please refer to our Terms and Conditions and Privacy Policy for more information about the cookies we use and how we protect your privacy.